At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Renal Autologous Cell Therapy (REACT)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label Safety and Tolerability Study of an Renal Autologous Cell Therapy (REACT) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)
In Brief
A Phase 2 clinical trial evaluating Renal Autologous Cell Therapy (REACT) for Type 2 Diabetes Mellitus and Chronic Kidney Disease. Completed, enrolled 10 participants across 4 sites.
Detailed Summary
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus, Chronic Kidney Disease
CountriesUnited States
CollaboratorsCTI Clinical Trial and Consulting Services
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartApr 2018
Primary CompletionNov 2022
TodayJul 2026
First PostedSep 1, 2017
Enrollment StartApr 25, 2018
Primary CompletionNov 17, 2022
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.8 years ago
Interventions
Renal Autologous Cell Therapy (REACT)biological
Autologous selected renal cells (SRC)